By studying classical (CL) and non-classical (NC) monocytes from RA patients defined by their pre-biologic treatment type I IFN activity, we can understand the functional impact of the IFN ratio on a key effector cell type. This evidence concerns the gene IFNA1 and rheumatoid arthritis.